Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Renin-Angiotensin-System (RAS)-Acting Agents Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The market for renin-angiotensin-system (ras)-acting agents has seen significant growth in recent years. It will grow from $6.11 billion in 2025 to $6.44 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. This historical expansion is attributable to several factors, including the high prevalence of hypertension, the increasing demographic of the aging population, the widespread acceptance of ACE inhibitors, enhanced cardiovascular screening initiatives, and the cost-effectiveness of generic drugs.
The renin-angiotensin-system (ras)-acting agents market is projected to experience significant expansion over the next few years. It is expected to reach $7.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period is attributed to the burden of chronic kidney disease, the demand for cardiometabolic drugs, improved treatment adherence, the expansion into emerging markets, and approvals for combination therapies. Key trends in the forecast period include the increasing use of combination antihypertensive treatments, the development of long-acting cardiovascular drugs, a rising focus on renal protection therapies, the expansion of generic RAS drug production, and a shift towards fixed-dose combinations.
Get A Free Sample Report With In-Depth Market Insights:
Renin-Angiotensin-System (RAS)-Acting Agents Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The expansion of the renin-angiotensin system (RAS)-acting agents market is anticipated to be driven by the growing incidence of hypertension. Hypertension, commonly known as elevated blood pressure, is a chronic medical condition marked by consistently high force of blood against artery walls. The rising occurrence of hypertension stems from unhealthy dietary choices, particularly diets high in salt and processed foods, which contribute to increased blood pressure and strain on the cardiovascular system. Renin-angiotensin system (RAS)-acting agents play a role in reducing hypertension by regulating blood pressure. They achieve this by inhibiting angiotensin II, a hormone known to constrict blood vessels and promote fluid retention, thereby fostering vasodilation and lowering blood pressure. For example, the World Health Organization, a Switzerland-based intergovernmental organization, estimated in September 2025 that in 2024, around 1.4 billion adults aged 30–79 worldwide were experiencing hypertension, which accounted for approximately 33% of individuals within this age group. This increasing prevalence of hypertension is therefore a significant factor propelling the growth of the renin-angiotensin system (RAS)-acting agents market.
Renin-Angiotensin-System (RAS)-Acting Agents Market Segments: Where Is Growth Concentrated?
The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –
1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes
2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril
2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan
3) By Renin Inhibitors: Aliskiren
4) By Aldosterone Antagonists: Spironolactone, Eplerenone
5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)
Renin-Angiotensin-System (RAS)-Acting Agents Market Innovation Trends Shaping Future Development
Major companies within the renin-angiotensin system (RAS)-acting agents market are intently focused on creating novel renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors. This development aims to boost effectiveness, lessen adverse effects, increase patient adherence, and address conditions such as hypertension, heart failure, and kidney diseases. An angiotensin-converting enzyme (ACE) inhibitor is a medication that works by lowering blood pressure through blocking the enzyme responsible for converting angiotensin I into angiotensin II, a substance known to narrow blood vessels. For example, in November 2023, Proveca Ltd., a UK-based pharmaceutical company, was awarded a grant by the European Commission for pediatric use marketing authorization (PUMA) for Aqumeldi (enalapril maleate) orodispersible tablets. These tablets are intended for the management of heart failure in children from birth to less than 18 years. Aqumeldi functions as an angiotensin-converting enzyme (ACE) inhibitor, treating pediatric heart failure patients by inhibiting the angiotensin-converting enzyme (ACE), thus preventing the conversion of angiotensin I to angiotensin II, which consequently relaxes blood vessels, improves blood flow, and decreases the heart’s workload.
Renin-Angiotensin-System (RAS)-Acting Agents Market Key Participants And Competitive Landscape
Major companies operating in the renin-angiotensin-system (ras)-acting agents market are Novartis AG, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences Limited
View The Full Renin-Angiotensin-System (RAS)-Acting Agents Market Report:
Renin-Angiotensin-System (RAS)-Acting Agents Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (ras)-acting agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model